Whalesbook
1. THE SEAMLESS LINK
This legal and financial deadlock highlights a broader struggle within India's healthcare system: balancing intellectual property rights with the fundamental right to life when faced with life-threatening, high-cost rare diseases. The government's National Rare Diseases Policy, 2021, offers limited financial support, creating a critical gap that patient advocacy groups are attempting to bridge through the courts.
Patent Law Under Scrutiny
Spinal Muscular Atrophy (SMA), a debilitating inherited neuromuscular condition, presents a stark case of treatment inaccessibility due to exorbitant costs. While gene therapy can exceed ₹17 crore, the oral solution Evrysdi, previously a primary medical recourse, carried an annual price tag of ₹72 lakh. Even with the introduction of the National Rare Diseases Policy (NRDP), 2021, the policy's ₹50 lakh one-time financial support is insufficient for many patients requiring ongoing, costly therapies. This policy, along with designated Centres of Excellence, has struggled to adequately address the financial burden of rare diseases, particularly those categorized under Group 3.
Natco's Intervention and Persistent Gaps
Natco Pharma has emerged as a key player in the domestic market by manufacturing a molecule similar to Evrysdi, dramatically reducing the cost to approximately ₹15,000 per vial. This brings the estimated annual treatment cost down to around ₹5 lakh. However, this figure, while significantly lower, still remains prohibitive for a substantial portion of the population. Furthermore, the Centers of Excellence are reportedly not yet consistently prescribing the more affordable generic versions, suggesting systemic inertia that impedes broader access. The limited efficacy of the NRDP's ₹50 lakh cap means that even with Natco's contribution, long-term or comprehensive treatment remains a significant financial challenge.
Legal Avenues Explored
In response to these systemic failures, patients and advocacy groups are increasingly leveraging legal channels. Seba, a 24-year-old SMA patient, exemplifies this push by seeking the invocation of Section 100 of the Patent Act, 1970. This seldom-used provision grants the government the power to utilize patented inventions for non-commercial public use, a safeguard enacted to prevent patent monopolies from obstructing access to essential medicines. This legal mechanism, designed to address public health emergencies, has historically been bypassed by Indian governments. Seba's case, joined by others, is now before the Supreme Court, questioning the constitutionality of the ₹50 lakh funding ceiling and arguing that the government's inaction constitutes a violation of the fundamental right to life under Article 21.
The Supreme Court's Role
The Supreme Court faces a critical juncture, tasked with adjudicating the adequacy of the ₹50 lakh cap on government assistance for rare diseases. The apex court's decision will not only impact the immediate cases before it but could also set a significant precedent for access to life-saving treatments in India. The court is expected to determine whether the government can be compelled to utilize provisions like Section 100 of the Patent Act to ensure affordable access to medicines, potentially influencing future government allocations towards research and indigenous manufacturing of critical drugs. Recent Supreme Court proceedings have included stays on High Court orders mandating drug provision beyond the ₹50 lakh cap, while also acknowledging the potential for case-by-case expenditure approvals and the cost-saving measures seen in other countries.
Market Context and Outlook
Natco Pharma, a vertically integrated pharmaceutical company focused on niche therapeutic areas, holds a market capitalization of approximately ₹14,554 crore as of late January 2026. Its Price-to-Earnings (P/E) ratio hovers around 9.46-10.36, indicating investor confidence in its earnings. The company's stock experienced fluctuations in late January 2026, trading within a range of roughly ₹813 to ₹946, reflecting market dynamics and ongoing news related to drug pricing and regulatory challenges. The broader Indian pharmaceutical sector is a global leader in generic drug production, yet faces considerable hurdles in developing and pricing orphan drugs for rare diseases due to high R&D costs and small patient populations. The evolving legal landscape, coupled with government policies like the NRDP and the newly established National Fund for Rare Diseases, will continue to shape the investment narrative for companies operating in this critical, albeit challenging, segment of the healthcare market.